Vaccinex, Inc. Vaccinex, Inc.

Vaccinex, Inc.

VCNX

Rank in Stocks #32023
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage,... Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.
Share Price
$1.00
Last synced: 2026-11-13
Market Cap
$2.10M
Change (1 day)
0.00%
Change (1 year)
51.13%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Vaccinex, Inc. (VCNX)
Operating Margin as of November 2026 TTM: -249.74%
According to Vaccinex, Inc.'s latest financial reports, its current operating margin (TTM) is -249.74%. At the end of 2025 the company had an operating margin of -249.74%.
Operating Margin history for Vaccinex, Inc. from 2016 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -249.74% 0.00%
2025 -249.74% -91.99%
2024 -3,117.30% -22.36%
2023 -4,014.91% -79.83%
2022 -19,906.00% 696.59%
2021 -2,498.89% -95.59%
2020 -56,662.00% 825.64%
2019 -6,121.41% 62.45%
2018 -3,768.09% -83.93%
2017 -23,448.89% 265.76%
2016 -6,411.08% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -99.22%
US
33.87% -100.14%
US
-116.04% -99.54%
US
25.57% -100.10%
AU
31.23% -100.13%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Vaccinex, Inc.'s operating margin

What is Vaccinex, Inc.'s operating margin?

Vaccinex, Inc.'s operating margin is -249.74%, as of Nov 2026.

What was Vaccinex, Inc.'s operating margin in 2025?

In 2025, Vaccinex, Inc.'s operating margin was -249.74%, compared with -3,117.30% in 2024.

How has Vaccinex, Inc.'s operating margin changed since 2020?

From 2020 to 2025, Vaccinex, Inc.'s operating margin was highest in 2025 (-249.74%) and lowest in 2020 (-56,662.00%).

How does Vaccinex, Inc.'s operating margin compare with similar companies?

Vaccinex, Inc.'s operating margin (-249.74%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.